)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Vigil Neuroscience (VIGL) investor relations material
Vigil Neuroscience Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Entered definitive merger agreement with Sanofi; shareholders to receive $8.00 per share in cash plus a $2.00 contingent value right tied to VG-3927 commercialization; merger expected to close in Q3 2025.
Phase 2 IGNITE trial for iluzanebart in ALSP discontinued after no efficacy observed; VG-3927 Phase 1 data showed favorable safety and PK/PD profile for Alzheimer's disease.
As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $67.0 million; accumulated deficit reached $356.1 million.
Company expects to continue incurring significant losses and will require additional funding if the merger does not close.
Financial highlights
Net loss for Q2 2025 was $26.7 million, compared to $21.2 million in Q2 2024; net loss for the six months ended June 30, 2025 was $49.1 million, up from $41.2 million year-over-year.
Research and development expenses for Q2 2025 were $17.4 million, up from $15.5 million in Q2 2024; general and administrative expenses rose to $10.1 million from $6.9 million.
Interest income declined to $0.8 million in Q2 2025 from $1.3 million in Q2 2024 due to lower cash balances.
Cash used in operating activities for the first half of 2025 was $44.4 million; net cash provided by financing activities was $13.5 million, primarily from ATM equity sales.
Outlook and guidance
Cash runway expected to fund operations into 2026; substantial doubt exists about ability to continue as a going concern without additional capital or successful merger.
Ongoing focus on advancing VG-3927 for Alzheimer's disease and expanding the microglia-targeted pipeline.
If the merger with Sanofi is not completed, additional funding will be sought through equity, debt, or strategic transactions.
Assess merger impact on VG-3927 development.
Explain the reasons for iluzanebart trial failure.
How will Sanofi deal with VIGL101 return?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vigil Neuroscience earnings date
Q3 20256 Nov, 2025
Next Vigil Neuroscience earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focusing on developing treatments for both rare and common neurodegenerative diseases. The company aims to enhance the function of microglia, which are critical immune cells in the brain, to combat these diseases. Vigil Neuroscience's approach involves using precision medicine to develop targeted drug candidates, particularly focusing on the triggering receptor expressed on myeloid cells 2 (TREM2). Their drug development programs are centered on activating TREM2 to address conditions associated with microglial dysfunction, such as Alzheimer's disease. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage